Herceptin resistance in HER2-moderately expressed breast cancer
<p>HER2 overexpression occurs in approximately 15-20% of all breast cancers and is associated with poor prognosis. The development of Herceptin, a monoclonal antibody against HER2, has been significant in prolonging survival of these patients. Herceptin is less efficient in patients who do not...
Autori principali: | , |
---|---|
Altri autori: | |
Natura: | Tesi |
Lingua: | English |
Pubblicazione: |
2012
|
Soggetti: |